相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10
J. E. Allen et al.
CANCER RESEARCH (2015)
Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner
Varun V. Prabhu et al.
CANCER RESEARCH (2015)
The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activity
Jessica Wagner et al.
ONCOTARGET (2014)
Small-molecule activation of the TRAIL receptor DR5 in human cancer cells
Gelin Wang et al.
NATURE CHEMICAL BIOLOGY (2013)
Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects
Joshua E. Allen et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Regulation of the human TRAIL gene
Joshua E. Allen et al.
CANCER BIOLOGY & THERAPY (2012)
Targeting TRAIL Death Receptor 4 with Trivalent DR4 Atrimer Complexes
Joshua E. Allen et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Oxaliplatin Uses JNK to Restore TRAIL Sensitivity in Cancer Cells Through Bcl-xL Inactivation
Joshua E. Allen et al.
GASTROENTEROLOGY (2011)
Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer
T. Trarbach et al.
BRITISH JOURNAL OF CANCER (2010)
A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies
D. Ross Camidge et al.
CLINICAL CANCER RESEARCH (2010)
TRAIL receptor signaling and therapeutics
Junaid Abdulghani et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2010)
A Better TRAIL Variant for Tumor Cell-Specific Targeting? - Letter
Edwin Bremer et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study
Constantijne H. Mom et al.
CLINICAL CANCER RESEARCH (2009)
Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study
Stephen Leong et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Human Bone Marrow-Derived Mesenchymal Stromal Cells Expressing S-TRAIL as a Cellular Delivery Vehicle for Human Glioma Therapy
Lata G. Menon et al.
STEM CELLS (2009)
TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death
Kageaki Kuribayashi et al.
CANCER BIOLOGY & THERAPY (2008)
Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer
F. Anthony Greco et al.
LUNG CANCER (2008)
Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers
Ruth Plummer et al.
CLINICAL CANCER RESEARCH (2007)
A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors
A. W. Tolcher et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1
Anthony W. Tolcher et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs
TM Ganten et al.
CLINICAL CANCER RESEARCH (2006)
Human B cells express functional TRAIL/Apo-2 ligand after CpG-containing oligodeoxynucleotide stimulation
TJ Kemp et al.
JOURNAL OF IMMUNOLOGY (2004)
Cytokines and BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOX03a transcription factor
S Ghaffari et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Targeting death and decoy receptors of the tumour-necrosis factor superfamily
A Ashkenazi
NATURE REVIEWS CANCER (2002)
分享论文
